Tardive dyskinesia (TD) is a disabling neurological side effect associated with long-term treatment with typical antipsychotics. Family studies and animal models lend evidence for hereditary predisposition to TD. The newer atypical antipsychotics pose a minimal risk for TD which is in part attributed to their ability to block the serotonin-2A (5-HT 2A ) receptor. 5-HT 2A receptors were also identified in the basal ganglia; a brain region that plays a critical role in antipsychotic-induced movement disorders. We tested the significance of variation in the 5-HT 2A receptor gene (HTR2A) in relation to the TD phenotype. Three polymorphisms in HTR2A, one silent (C102T), one that alters the amino acid sequence (his452tyr) and one in the promoter region (A-1437G) were investigated in 136 patients refractory or intolerant to treatment with typical antipsychotics and with a DSM-IIIR diagnosis of schizophrenia. We did not find any significant difference in allele, genotype or haplotype frequencies of polymorphisms in HTR2A among patients with or without TD (P Ͼ 0.05). Further analysis using the ANCOVA statistic with a continuous measure of the TD phenotype (Abnormal Involuntary Movement Scale (AIMS) score) found that the AIMS scores were not significantly influenced by HTR2A polymorphisms, despite controlling for potential confounders such as age, gender and ethnicity (P Ͼ 0.05). Theoretically, central serotonergic function can be subject to genetic control at various other mechanistic levels including the rate of serotonin synthesis (tryptophane hydroxylase gene), release, reuptake (serotonin transporter gene) and degradation (monoamine oxidase gene). Analyses of these other serotonergic genes are indicated. In summary, polymorphisms in HTR2A do not appear to influence the risk for TD. Further studies evaluating in tandem multiple candidate genes relevant for the serotonergic system are warranted to dissect the genetic basis of the complex TD phenotype. Molecular Psychiatry (2001) 6, 230-234.
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Tardive dyskinesia (TD) is a disabling and potentially irreversible movement disorder that occurs in approximately 20-30% of patients during long-term treatment with typical antipsychotics. 1, 2 Although the precise molecular mechanisms of TD are not well understood, family studies and animal models lend evidence for hereditary predisposition to TD. [3] [4] [5] [6] Recently, genetic variability in several biological targets relevant for antipsychotic pharmacodynamics and pharmacokinetics were implicated in the pathophysiology of TD. For example, polymorphisms in the genes coding for the dopamine D3 receptor (DRD3), as well as in the cytochrome P450 2D6 and 1A2 enzymes (CYP2D6; CYP1A2) and manganese superoxide dismutase (MnSOD) appear to make modest but significant contributions to the overall variability in TD risk. [7] [8] [9] [10] [11] [12] [13] However, these genetic polymorphisms do not fully account for person-to-person differences in predisposition to TD and hence, further studies are necessary to delineate the genetic basis of the complex TD phenotype.
Historically, upregulation of the dopamine D2 receptor during chronic antipsychotic treatment has been one of the prevailing mechanistic hypotheses of TD. On the other hand, there are several reasons to think that the serotonin (5-hydroxytryptamine, 5-HT) system also contributes to TD. For example, most typical antipsychotic agents display a high affinity for dopamine D2 and D3 receptors, both of which have been suggested in the etiopathogenesis of TD. 9 5-HT is an indoleamine neurotransmitter and plays an important role in the regulation of dopaminergic neurotransmission. 14 Serotonergic neurons originating from the dorsal raphe exert tonic inhibitory control on the nigrostriatal dopaminergic input to the basal ganglia; a brain region that plays a critical role in antipsychotic-induced movement disorders. 15 The atypical antipsychotics such as clozapine pose a minimal risk for TD and exhibit a low affinity for dopamine D2 receptors while they act as potent 5-HT 2A receptor antagonists. 16, 17 It is thought that antagonism at the 5-HT 2A receptor and/or a high 5-HT 2A /D2 affinity ratio (Ͼ1.0) may confer atypical antipsychotic attributes such as a low TD risk. 16, 17 Moreover, 5-HT 2A receptors were identified in the basal ganglia. 16, 17 Taken together, it is likely that variation in the 5-HT 2A receptor gene (HTR2A) may influence sero-tonergic and dopaminergic neurotransmission and thereby contribute to risk for TD. In light of these findings, the 5-HT 2A receptor becomes an interesting candidate to study in the etiopathogenesis of TD.
The present study evaluated the significance of variation in HTR2A in relation to the TD phenotype. Three polymorphisms in HTR2A, one silent (C102T), one that alters the amino acid sequence (his452tyr) and one in its promoter region (A-1437G) were investigated in 136 patients with a DSM-IIIR diagnosis of schizophrenia. Written and informed consent was obtained from each patient.
The demographic attributes of the patients are presented in Table 1 . All patients were either treatment-refractory or intolerant to typical antipsychotics. Although detailed neuroleptic treatment history was not available, it was known that all patients had been treated with typical antipsychotics from at least two different chemical classes for a minimum of 1 year. 7, 10 Patients received at least three periods of treatment in the preceding 5 years at doses equivalent to or greater than 1000 mg day −1 chlorpromazine for a period of at least 6 weeks, each without significant symptomatic improvement. The Abnormal Involuntary Movement Scale (AIMS) was used to assess TD severity following a wash-out period of 2-4 weeks for typical antipsychotics. Patients who received an AIMS rating of mild dyskinesia in two or more body areas, or of moderate or severe dyskinesia in one or more body areas were categorized as having TD according to the Research Diagnostic Criteria for TD. 18 There were no significant differences in allele or genotype frequencies for each of the three polymorphisms in HTR2A gene in patients with or without TD (P Ͼ 0.05) ( Table 2 ). Our sample had 80% power to detect an association with an odds ratio of 2.21, setting 16 , df = 7, P = 0.32). Further analyses using the ANCOVA statistic demonstrated that the AIMS scores were not influenced by any of the HTR2A polymorphisms, after controlling for potential confounders such as age, gender, ethnicity, clinical site and prior response to typical antipsychotics (treatment-refractory vs treatmentintolerant) (P Ͼ 0.05) (Figure 1 ). Stratified analyses investigating Caucasians separately from AfricanAmericans did not reveal any associations between TD and HTR2A polymorphisms in either ethnic group. In addition, analyses distinguishing oro-facial TD from TD in the trunk and extremities, did not find any associations. There was no significant deviation from Hardy-Weinberg equilibrium for the three HTR2A genetic polymorphisms in our sample (P Ͼ 0.05). We found that the A-1437G and the C102T polymorphisms were in strong, but not complete, linkage disequilibrium ( ; disequilibrium coefficient ␦ = ± 0.223), consistent with previous analysis. 19 The composition of the patient sample was similar across the three study sites with the exception of age (Table 1) . However, our analyses were corrected for age. Results from an ANCOVA analysis of AIMS against genotype class, with several variables incorporated as covariates are presented below the plot. In addition, category sample size and AIMS scores (mean ± SD) for each genotypic class per polymorphism are also shown. All the assumptions of the ANCOVA were met in our sample. No statistically significant differences were found among the mean AIMS scores for HTR2A genotypes at any of the HTR2A polymorphisms investigated. The genotype axis is labeled using numeric alleles. For the A-1437G, C102T and His452Tyr polymorphisms, allele 1 respectively corresponds to the A allele, T allele and Tyr allele.
Molecular Psychiatry
There is considerable evidence that genetic factors play an important role in the etiology of TD. [3] [4] [5] [6] 9 However, the results of our study suggest that genetic variation in HTR2A does not significantly contribute to risk for TD. The candidate gene approach used in the present report is ideal to detect genetic loci that make small or modest contributions to drug response phenotypes. 20 Moreover, we studied all three known polymorphisms in the HTR2A gene in tandem but we could not detect an association with the TD phenotype, despite using both a dichotomous and a continuous measure of TD. On the other hand, genetic association studies are subject to confounding by genetic locus heterogeneity in the sample, which may lead to both falsepositive and false-negative results. 20 In our study, we tried to control for potential genetic heterogeneity by incorporation of ethnicity as a co-variate in the analysis. In theory, central serotonergic function can be subject to genetic control at various mechanistic levels including the rate of serotonin synthesis (tryptophane hydroxylase gene), release, reuptake (serotonin transporter gene) and degradation (monoamine oxidase gene). It is likely that our findings might have been confounded by genetic variability in other serotoninrelated candidate genes.
An additional confounding factor could be the epigenetic regulation of HTR2A. 21 HTR2A is subject to complicated epigenetic regulation, called polymorphic genomic imprinting (reviewed by Petronis 21 ). Genomic imprinting refers to parent-of-origin dependent epigenetic marking of genes leading to differential expression of such genes. In the case of HTR2A, the imprinting is polymorphic, that is, some individuals express both HTR2A alleles while others express only one HTR2A allele. 21 In other words, some individuals are in the state of functional hemizygosity. 21 It is of importance to know how many individuals express one and how many individuals express both HTR2A alleles in the groups of patients who developed TD and patients who did not. Lastly, the AIMS score provides a reliable overall description of TD but does not address the clinical heterogeneity of TD which may also explain discrepancies in the findings of genetic association studies.
In summary, HTR2A genetic polymorphisms did not appear to influence the risk for TD in our sample of schizophrenia patients who were refractory or intolerant to typical antipsychotics. Further studies evaluating in tandem multiple candidate genes relevant for the serotonergic system are warranted to dissect the genetic basis of the complex TD phenotype.
Methods

Genotyping
Genomic DNA was extracted from whole blood using a non-enzymatic, high-salt procedure. 22 The silent C102T polymorphism at the HTR2A locus was genotyped employing a modified protocol of Warren and colleagues. 23 The PCR reaction was performed using 150 ng of genomic DNA, 2.0 mM MgCl 2 , 0.4 M of both forward (5Ј-TCT GCT ACA AGT TCT GGC TT-3Ј) and reverse primer (5Ј-CTG CAG CTT TTT CTC TAG GG-3Ј), 200 M each of dATP, dCTP, dGTP, and dTTP, and 1 unit of AmpliTaq DNA polymerase in a final reaction volume of 25 l. The PCR program consisted of 30 cycles of 94°C for 30 s, 61°C for 1 min, and 72°C for 30 s with a final extension period of 72°C for 5 min. The amplified product was digested with Mspl at 37°C overnight, followed by electrophoresis on a 2.5% agarose gel at 100 V for 1 h, to yield fragments of 216 bp and 126 bp in the presence of the 102T allele, or the single uncut 342-bp fragment in the presence of the 102C allele.
The HTR2A his452tyr polymorphism was genotyped using a modified protocol of Ozaki and colleagues. 24 The PCR reaction was performed using 150 ng of genomic DNA, 1 mM MgCl 2 , 0.6 M of both forward (5Ј-CAC ACA GCT CAC CTT TTC ATT CA-3Ј) and reverse primer (5Ј-AGT CTA GCC AAC TTC AAA TGG-3Ј), 160 M each of dATP, dCTP, dGTP, and dTTP, and 1 unit of AmpliTaq DNA polymerase in a final reaction volume of 25 l. The PCR program consisted of 35 cycles of 95°C for 30 s, 58°C for 30 s, and 72°C for 30 s with a final extension period of 72°C for 5 min and yielded a 155-bp product. This product was then digested with Bsml restriction endonuclease and the presence of the common 452His allele yielded two fragments of 95 bp and 60 bp while the 452Tyr allele produced a single uncut fragment.
The protocol for the genotyping assay for the A-1437G promoter polymorphism was obtained from Nö then and colleagues. 25 The sequence of the forward primer Pro2F was 5Ј-CTA GCC ACC CTG AGC CTA TG-3Ј; the sequence of the reverse primer Pro2R was 5Ј-TTG TGC AGA TTC CCA TTA AGG-3Ј. The PCR reaction was performed using 150 ng of genomic DNA, 1 mM MgCl 2 , 0.6 M of both forward and reverse primer, 160 M each of dATP, dCTP, dGTP, and dTTP, and 1 unit of AmpliTaq DNA polymerase in a final reaction volume of 25 l. The PCR program consisted of 30 cycles of 95°C for 30 s, 59°C for 30 s, and 72°C for 30 s. The PCR product was then digested with MspI restriction endonuclease. After restriction digestion, the products were separated on a 3% agarose gel by electrophoresis which was stained with ethidium bromide for UV visualization. An uncut fragment of 200 bp was observed when there was an A at position −1437 while a G at this position led to two fragments of length 121 bp and 79 bp.
Statistical methods
The statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS), version 10.0. Chi-square tests were used to compare genotype and allele counts between schizophrenia patients with and without TD. Analysis of Covariance (ANCOVA) was used to compare the mean AIMS scores for each of the genotypic classes, in a method similar to that of Basile and colleagues. 7, 10 The ANCOVA statistic allowed the incorporation of several covariates into the statistical model. The demographics of our sample were statistically analyzed in order to determine any effects of sex and ethnicity that may have confounded the ANCOVA statistic. The assumptions of the ANCOVA statistic were tested in order to determine the appropriateness of our sample. The assumption of equal variance among each genotypic class was verified using the Levene Test for homogeneity of variances. The assumption of categorical groups with normally distributed values was tested for each genotypic panel using Kolmogorov-Smirnov Z tests. Chi-square tests were used in order to test whether the distribution of genotypes for each polymorphism was in accordance with Hardy-Weinberg equilibrium. Power estimations for the case control statistics were calculated using EPI Info Version 5.01a. Power calculations for the ANCOVA were performed based on mean AIMS scores and sample sizes, with alpha set to 0.05. Linkage disequilibrium among the HTR2A polymorphisms was assessed using the linkage utility program (EH). The EH program was also used to compare the associations between the genetic haplotypes and the TD phenotype. These methods were described previously. 19 
